Respiratory & Immunology

Our ambition is to transform Respiratory & Immunology care for patients, moving beyond symptom control to disease modification, remission and, one day, cure.

Home / Our therapy areas / Respiratory & Immunology



Our commitment

With five decades of experience, we are an established leader in respiratory care and a disruptor in immunology. We are committed to transforming care for some of the most debilitating and chronic respiratory and immune-mediated diseases. Our portfolio of inhaled and biologic medicines, and our pipeline for the future, seek to address the challenges and vast unmet medical needs patients face today. By following the science, we are focused on sustainably addressing tough and complex unsolved problems. Our approach involves targeting the underlying biology, developing effective new drug modalities and combinations and applying a precision medicine approach from the start of discovering medicines, all while driving earlier detection, diagnosis and intervention.



Transforming the lives of patients with respiratory and immune-mediated diseases

Hear how we are addressing tough challenges to make a difference for patients – including advancing the science beyond just symptom control, uncovering true drivers of disease, using new modalities, and reimagining our work with partners.







Our focus areas

We are focused on chronic respiratory diseases including asthma and chronic obstructive pulmonary disease (COPD), as well as immune-driven diseases such as lupus. We follow the science to address tough and complex, unsolved problems - targeting the underlying biology and developing effective new drug modalities and combinations with the ultimate ambition of achieving disease modification and clinical remission.

Click on the links below to learn more about our focus areas:





Our people

We are an established leader in Respiratory medicine and a disruptor in Immunology and we invest in and value our people. We are positioned to follow the science in our research, while also solving issues in treatment and management of respiratory and immune-mediated diseases. Our culture is rooted in integrity, inclusiveness, and our dedication to joining and supporting the communities in which we live and work. 

The Respiratory & Immunology team is led by:



It is an exciting time to work in Respiratory & Immunology, as we continue to work towards transforming care for some of the most debilitating and chronic respiratory and immune-mediated diseases. By targeting the underlying biology and applying a precision medicine approach from the start of discovering medicines, we aim to move beyond symptom control to disease modification, remission and one day, cure.

Maria Belvisi, Senior Vice President and Head of Research and Early Development, Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca





Join our team

Our Respiratory & Immunology therapy area is driven by innovation and our commitment to make a real-life difference in patient’s lives. That difference starts with you. IDEA Pharma ranked us #1 on their Invention Index and #2 on their Innovation Index and we are recognised as a top employer in 2021/2022 by Forbes, Financial Times and Biospace. We need people like you who share our passion for science and determination to meet patients’ needs around the world.

Visit our careers website and:








Collaboration

Through collaboration and partnerships, we can accelerate positive change and outcomes for patients. We work with leading research and academic institutions, public health authorities, patient groups and professional organisations across respiratory and immune-mediated diseases.




Our medicines

We cannot provide detailed information about our prescription medicines on this website, in compliance with regulations.Our medicines are approved in individual countries for specific uses and the information we provide for patients is governed by local regulations. In some cases, healthcare professionals and patients can visit local AstraZeneca websites to find out more about our medicines. Please note that in some countries we are not allowed to provide very much, or sometimes any, information on our prescription medicines so you should seek alternative trustworthy sources. Always ask a healthcare professional for advice about medicines.


Accolate, Accoleit, Vanticon

zafirlukast

Bevespi Aerosphere

glycopyrronium/formoterol fumarate

Breztri Aerosphere

budesonide/glycopyrronium/formoterol fumarate

Bricanyl Respules

terbutaline

Bricanyl Turbuhaler

terbutaline in a dry powder inhaler

Daliresp/Daxas

roflumilast

Duaklir Genuair

aclidinium/formoterol

Eklira Genuair/Tudorza/Bretaris

aclidinium, a LAMA

Fasenra

benralizumab

Oxis Turbuhaler

Oxis Turbuhaler

Pulmicort Respules

budesonide inhalation suspension

Pulmicort Turbuhaler

budesonide

Rhinocort

budesonide

Saphnelo

anifrolumab

Symbicort pMDI

budesonide/formoterol

Symbicort Turbuhaler

budesonide/formoterol

Tezspire

tezepelumab




Our pipeline for R&I

Our pipeline forms a robust portfolio of investigational therapies in varied stages of clinical development.

Phase III/Reg. refers to assets that are in Phase III or that have been submitted for regulatory approval and may include assets that are now launched in one or more major markets.


Respiratory & Immunology (as of 8 February 2024)

Phase I

Phase I

Phase II

Phase II

Phase III

Phase III

LCM Projects

LCM Projects







References

1. United Nations. Sustainable Development Goals. Available at: http://www.un.org/sustainabledevelopment/sustainable-development-goals/. [Last accessed: August 2022].

2. World Health Organization. COPD Factsheet. Available at: http://www.who.int/news-room/fact-sheets/detail/chronic-obstructive-pulmonary-disease-(copd). [Last accessed: August 2022].

3. Chen S, et al. Systematic literature review of the clinical, humanistic, and economic burden associated with asthma uncontrolled by GINA Steps 4 or 5 treatment. Curr Med Res Opin. 2018;34:2075–2088

4. Peters SP, et al. Uncontrolled asthma: a review of the prevalence, disease burden and options for treatment. Respir Med. 2006: 100 (7): 1139-51. 


Veeva ID: Z4-51416
Date of preparation: December 2022